NI200700217A - Formas cristalinas y amorfas del clohidrato 4-ciano-n-{(2r)-2-[4-(2,3-dihidro-benzo [1,4]dioxin-5-il)-piperazin -1-il]-propil}-n-piridin-2-il-benzamida. - Google Patents

Formas cristalinas y amorfas del clohidrato 4-ciano-n-{(2r)-2-[4-(2,3-dihidro-benzo [1,4]dioxin-5-il)-piperazin -1-il]-propil}-n-piridin-2-il-benzamida.

Info

Publication number
NI200700217A
NI200700217A NI200700217A NI200700217A NI200700217A NI 200700217 A NI200700217 A NI 200700217A NI 200700217 A NI200700217 A NI 200700217A NI 200700217 A NI200700217 A NI 200700217A NI 200700217 A NI200700217 A NI 200700217A
Authority
NI
Nicaragua
Prior art keywords
dioxin
piperazin
benzo
clohydrate
benzamida
Prior art date
Application number
NI200700217A
Other languages
English (en)
Inventor
Eric N C Browne
Michel Bernatchez
Mark Lankau
Anthony F Hadfield
Abdolsamad Tadayon
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NI200700217A publication Critical patent/NI200700217A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a formas cristalinas y amorfas del receptor antagonista 5-HT1A del clorhidrato 4-ciano-N-{(2R)-2 -[4-(2,3-dihidro-benzo[1,4]dioxin-5-il)-piperazin-1-il]-propil}-N-piri din-2-il-benzamida, así como también a las composiciones de los mismos y los métodos para usar dichas composiciones.-
NI200700217A 2005-03-01 2007-08-21 Formas cristalinas y amorfas del clohidrato 4-ciano-n-{(2r)-2-[4-(2,3-dihidro-benzo [1,4]dioxin-5-il)-piperazin -1-il]-propil}-n-piridin-2-il-benzamida. NI200700217A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65757505P 2005-03-01 2005-03-01

Publications (1)

Publication Number Publication Date
NI200700217A true NI200700217A (es) 2008-07-24

Family

ID=36659970

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700217A NI200700217A (es) 2005-03-01 2007-08-21 Formas cristalinas y amorfas del clohidrato 4-ciano-n-{(2r)-2-[4-(2,3-dihidro-benzo [1,4]dioxin-5-il)-piperazin -1-il]-propil}-n-piridin-2-il-benzamida.

Country Status (19)

Country Link
US (2) US20070027162A1 (es)
EP (1) EP1853593A1 (es)
JP (1) JP2008531694A (es)
KR (1) KR20070112797A (es)
CN (1) CN101137648A (es)
AR (1) AR053152A1 (es)
AU (1) AU2006218845A1 (es)
BR (1) BRPI0609370A2 (es)
CA (1) CA2599588A1 (es)
CR (1) CR9319A (es)
GT (1) GT200600098A (es)
IL (1) IL185267A0 (es)
MX (1) MX2007010524A (es)
NI (1) NI200700217A (es)
NO (1) NO20074254L (es)
PE (1) PE20061344A1 (es)
RU (1) RU2007131044A (es)
TW (1) TW200700413A (es)
WO (1) WO2006093853A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600403A (es) * 2005-09-09 2007-09-19 Composiciones y formas de dosificacion farmaceuticas

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645681B2 (en) * 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5568992A (en) * 1995-05-19 1996-10-29 Caterpillar Paving Products Inc. Screed control system for an asphalt paver and method of use
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6287839B1 (en) * 1997-11-19 2001-09-11 Genencor International, Inc. Cellulase producing actinomycetes, cellulase produced therefrom and method of producing same
US6127062A (en) * 1998-03-24 2000-10-03 Duracell Inc End cap seal assembly for an electrochemical cell
TR200100698T2 (tr) * 1998-09-10 2001-07-23 F.Hoffmann-La Roche Ag 5-HT4 alıcı-Antagonistleri olarak Dihidrobenzodioksin Karboksamit ve Keton türevleri
IT1318394B1 (it) * 2000-03-17 2003-08-25 Enichem Spa Processo per la preparazione di 1-esene.
US6469007B2 (en) * 2000-11-28 2002-10-22 Wyeth Serotonergic agents
RU2315762C2 (ru) * 2002-03-12 2008-01-27 Уайт Способ синтеза хиральных n-арилпиперазинов
US7091349B2 (en) * 2002-03-12 2006-08-15 Wyeth Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
ES2283762T3 (es) * 2002-03-12 2007-11-01 Wyeth Preparacion de acido n1-(2'-piridil)-1,2-propanodiaminosulfamico y su uso en la sintesis de piperazinas biologicamente activas.
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20050209245A1 (en) * 2004-03-19 2005-09-22 Wyeth Process for preparing N-aryl-piperazine derivatives
TWI257220B (en) * 2005-03-25 2006-06-21 Ind Tech Res Inst Cross-layer rate adaptation mechanism for WLAN

Also Published As

Publication number Publication date
CR9319A (es) 2008-01-21
US20090192311A1 (en) 2009-07-30
AR053152A1 (es) 2007-04-25
RU2007131044A (ru) 2009-04-10
CN101137648A (zh) 2008-03-05
US20070027162A1 (en) 2007-02-01
KR20070112797A (ko) 2007-11-27
EP1853593A1 (en) 2007-11-14
CA2599588A1 (en) 2006-09-08
JP2008531694A (ja) 2008-08-14
WO2006093853A1 (en) 2006-09-08
MX2007010524A (es) 2008-01-16
TW200700413A (en) 2007-01-01
GT200600098A (es) 2006-11-09
IL185267A0 (en) 2008-02-09
AU2006218845A1 (en) 2006-09-08
PE20061344A1 (es) 2007-01-03
NO20074254L (no) 2007-09-24
BRPI0609370A2 (pt) 2010-03-30

Similar Documents

Publication Publication Date Title
ECSP109987A (es) Métodos y compuestos útiles para preparar inhibidores del co-transportador 2 sodio glucosa
AR047088A1 (es) Polimorfo cristalino de piridinetilennaftofurano como antagonista del receptor de trombina, metodo de obtencion y composiciones farmaceuticas
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
CU20100115A7 (es) Intermedios útiles para la preparación de derivados de carboxamida como antagonistas del receptor muscarínico
EA201200506A1 (ru) СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ)БЕНЗОЛА
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
CR10922A (es) Derivados de indol como antagonistas receptores de s1p1
AR058670A1 (es) Ciclopropil aminas como moduladores del receptor h3 de histamina. composiciones farmaceuticas
CL2003002762A1 (es) Compuestos derivados de pirrolopirimidina o pirrolopiridina sustituidas por una amina ciclica, sus sales; composicion farmaceutica; y su uso para preparar un antagonista de los receptores de crf, para tratar enfermedades como depresion, ansiedad, alz
CL2006003737A1 (es) Uso de compuestos derivados de triazina o pirimidina sustituida, para tratar o prevenir enfermedades mediadas por los receptores de prokineticina 2 tales como trastornos gastrointestinales.
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
ECSP066866A (es) Formas de dosificación y composiciones farmacéuticasreferencia a las solicitudes relacionadas
DK1824479T3 (da) Phenylpiperazin-derivater med en kombination af delvis dopamin-D2-receptoragonisme og serotonin-genoptagelsesinhibering
DE602005009977D1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
DK2470166T3 (da) Nye sammensætninger af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazin
CR10846A (es) Formas cristalinas glyt1
DE602006020450D1 (de) Ykinin-rezeptorantagonisten
BRPI0916657A2 (pt) pirrolidin-3-ilmetil-amina como antagonistas de orexina
GT200600116A (es) Derivados de aril 1,4-pirazina sustituidos
UY29733A1 (es) Piperazinas acetilenicas como antagonistas de receptores de glutamato metabotrópicos
ECSP077979A (es) Potenciadores del receptor ampa
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
NI200700217A (es) Formas cristalinas y amorfas del clohidrato 4-ciano-n-{(2r)-2-[4-(2,3-dihidro-benzo [1,4]dioxin-5-il)-piperazin -1-il]-propil}-n-piridin-2-il-benzamida.
UY29481A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como antiinflamatorios.